LEO Pharma Secures $1.7 Billion Funding to Transform Dermatology Care Worldwide

LEO Pharma, a leading global pharmaceutical company dedicated to improving the lives of individuals suffering from skin conditions, has successfully raised a remarkable DKK 1.7 billion (approximately €230 million) in a recent funding round. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has consistently focused on advancing dermatological care through decades of research and development. The influx of capital will be strategically allocated to bolster the company’s innovative pipeline, enhance its existing therapies, and expand its reach in underserved markets across the globe. With a dedicated workforce of over 4,200 professionals, LEO Pharma is committed to serving millions of patients worldwide, and the new funding will enable them to further their mission to transform dermatological care. In 2023, the company achieved significant success with net sales amounting to DKK 11.4 billion, reinforcing LEO Pharma's vital role in the industry. By leveraging this investment, LEO Pharma aims to accelerate clinical trials for groundbreaking treatments, develop next-generation therapies, and ultimately, improve the standard of living for those affected by various skin conditions. As the company continues to break new ground in dermatological science, it remains steadfast in its commitment to patients, families, and healthcare providers, ensuring that everyone receives the highest quality of care and support.